Brain biopsy in AIDS patients: diagnostic yield and treatment applications by unknown
Zibly et al. AIDS Research and Therapy 2014, 11:4
http://www.aidsrestherapy.com/content/11/1/4SHORT REPORT Open AccessBrain biopsy in AIDS patients: diagnostic yield
and treatment applications
Zion Zibly7, Itzchak Levy3, Vlady Litchevski3, Dvora Nass2, Chen Hofmann4, Jacob Barham5, Christian A Graves6,
Roberto Spiegelmann1, Moshe Hadani1 and Zvi R Cohen1*Abstract
Objective: Central nervous system involvement in AIDS patients can present at any stage of the disease. Brain
lesions detected in imaging studies are usually treated empirically. A brain biopsy is indicated in the absence of
clinical and radiologic improvement. In the present study, 16 AIDS patients underwent brain biopsy. We evaluated
the diagnostic yield of the brain biopsy and the changes in the disease course.
Materials and methods: Sixteen consecutive AIDS patients (12 men, 4 women; mean age 40.8 years) underwent a
brain biopsy at Sheba Medical Center between 1997 and 2009. A retrospective analysis was performed and the
clinical outcome was recorded.
Results: Median CD4 count before biopsy was 62.6. Magnetic resonance images revealed multiple lesions in 12
patients and enhancing lesions in 12 patients. A total of 19 biopsies were performed in 16 patients. In the present
series, the initial procedures provided a diagnostic yield of 81.25% (13 diagnostic cases from 16 procedures in 16
patients). Two of these patients underwent repeated biopsies that were eventually diagnostic . If repeated biopsies
were taken into consideration, the diagnostic yield was 93.75% (15 diagnostic cases in 16 patients). The rate of
hemorrhagic complications was 10.5% (2 hemorrhages in 19 procedures).
Pathologic examination revealed parasitic and fungal infections in 6 patients (6/16; 38%), progressive multifocal
leukoencephalopathy in 4 patients (4/16; 25%), AIDS encephalopathy in 4 patients (4/16; 25%), and lymphoma in 1
patient (1/16; 6%). One patient had a nonspecific inflammatory process (6%). The treatment modality was modified
in 12 patients and led to clinical and radiologic improvement in 8 patients.
Conclusions: Brain biopsy should be considered when empiric treatment of central nervous system lesions in AIDS
patients fails. Biopsy is diagnostic in the majority of patients. The diagnosis allows for treatment modifications,
which lead to clinical and radiologic improvement in some patients.
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Central nervous system (CNS) involvement in AIDS pa-
tients is a well-established phenomenon that occurs in ap-
proximately 40% to 60% of patients at some stage of the
disease. In 10% to 20% of patients, neurologic complica-
tions are the first manifestation of HIV infection [1]. The
causes of brain involvement include infection, inflamma-
tory changes, and neoplasia [2]. The most common brain
lesion in HIV patients worldwide is toxoplasmosis [3],
but there is an increased incidence of HIV-associated* Correspondence: Zvi.Cohen@sheba.health.gov.il
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reproduction in any medium, provided the ortuberculosis in focal brain lesions in developing coun-
tries [4]. Imaging characteristics of brain lesions in HIV
patients have been described [5,6]. The diagnostic yield
of brain biopsy in HIV patients has also been evaluated
[7-9]. In recent years, due to the availability of advanced
multidrug therapies such as highly active antiretroviral
therapy (HAART), the disease has gained more chronic
characteristics and patient prognosis has greatly im-
proved. The increased longevity of the clinical course of
AIDS patients requires the establishment of more ag-
gressive therapeutic approaches in patients with CNS
involvement. Brain lesions detected on imaging studies are
treated empirically according to current clinical guidelines.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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radiologic improvement, based on the recommendations of
the National Institutes of Health (NIH), the Centers for
Disease Control and Prevention (CDC), and the HIV
Medicine Association of the Infectious Diseases Society of
America. The objective of this retrospective study was to
analyze the data of 16 AIDS patients who underwent a
brain biopsy at Sheba Medical Center in Israel to evaluate
the diagnostic yield and changes in the disease course.
Material and methods
Patient selection and study approval
The study was conducted according to procedures ap-
proved by the Sheba Medical Center Institutional Review
Board.
Clinical data
Sixteen consecutive AIDS patients underwent a brain bi-
opsy at Sheba Medical Center between 1997 and 2009.
Patient characteristics; presenting symptoms; neurologic
status; CD4 count; radiologic imaging results, including
number of lesions, location of the targeted lesion, and
presence of post-operative hemorrhage on computed
tomography (CT) scans; and pathologic results were
retrospectively analyzed. Treatment changes, and clinical
and radiologic outcome were recorded.
Surgical procedure
Stereotactic brain biopsies were performed using a Radi-
onics® CRW™ frame and localizer (except for one patient
that underwent an open image-guided navigation system
biopsy using pituitary forceps). After performing the CT
scan and establishing the target (based on fusion with
preoperative MR images and performed by the neuro-
surgeon), the patient was taken to the operating room
and serial stereotactic biopsies were obtained under local
anesthesia along the established trajectory using a side-
cutting biopsy needle. CT scans were obtained up to
2 hours post-procedure and the patients remained in the
neurosurgical department for overnight observation.
Tissue analysis
Tissue specimens collected in the operation room were
placed in individual vials for pathologic analysis; incu-
bated in aerobic, anaerobic, mycobacterium, and fungal
cultures; and subjected to PCR analysis for the JC and
BK polyomaviruses.
Results
Twelve patients were men. Mean age at onset of the
neurologic manifestations was 40.8 years. The clinical
manifestations of the disease were mainly cognitive
changes and motor deficits. Mean CD4 count before the
brain biopsy was 62.6. A total of 19 brain biopsies wereperformed in 16 patients. In the present series, the initial
procedures provided a diagnostic yield of 81.25% (13
diagnostic cases from 16 procedures in 16 patients).
Two of these patients underwent repeated biopsies that
were eventually diagnostic. If repeated biopsies were
taken into consideration, the diagnostic yield was 93.75%
(15 diagnostic cases in 16 patients).
Among the three patients with an initially nondiagnos-
tic biopsy, the initial biopsy revealed a nonspecific in-
flammatory process in two patients, and the procedure
was aborted due to hemorrhage in one patient. Two of
these patients underwent a repeated biopsy that was
eventually diagnostic.
One of the patients initially diagnosed with a nonspe-
cific inflammatory process underwent two more biopsies
and the third biopsy was eventually diagnostic. The sec-
ond patient initially diagnosed with a nonspecific inflam-
matory process improved with HAART and did not
require a second biopsy.
In the present series, the rate of hemorrhagic compli-
cations was 10.5% (2 hemorrhages in 19 procedures).
Two of our patients had a hemorrhage; the first had a
non-surgical bleeding however we had to abort the pro-
cedure and the patient underwent later a second proced-
ure with a diagnostic biopsy. The second patient had a
diagnostic biopsy, but due to clinical deterioration
underwent evacuation of a hematoma. This patient re-
covered from the procedure, but did not improve with
HAART.
Pathologic examination revealed parasitic and fungal
infections in 6 patients (6/16) [38%]: toxoplasmosis, N =
4 [67%], aspergillosis N = 1 [17%], and cryptococcosis
N = 1 [17%]), progressive multifocal leukoencephalopa-
thy (PML) in 4 (25%) patients, AIDS encephalopathy in
4 patients (25%), and lymphoma in 1 (6%) patient. One
patient had a nonspecific inflammatory process (6%),
The treatment modality was modified in 12 patients and
led to clinical and radiologic improvement in 8 patients
(Table 1).
Discussion
Treatment with highly active antiviral drugs (HAART)
has resulted in an overall decline in morbidity and mor-
tality among HIV-infected patients with advanced dis-
ease [10]. The widespread use of prophylactic regimens
has changed the disease pattern and decreased the inci-
dence of opportunistic infections [11]. Vago et al. [12]
reported on a large autopsy series that showed a signifi-
cant reduction in the frequency of HIV-related central
nervous system lesions in AIDS patients since the begin-
ning of the HAART era.
In patients with HIV, Toxoplasma gondii is the most
frequent infectious cause of focal brain lesions [3]. Toxo-
plasmic encephalitis has a subacute onset with focal













1 PML 37 sbx Male Multiple BG Right No None Combined 69 AZT, 3TC No No
2 Non diagnostic × 1,
Toxoplasmosis 2nd
36 sbx Male Solitary Frontal Right Yes Yes Motor 50 AZT, 3TC,
Antitoxoplasmosis
Bleeding No
3 PML 41 sbx Male Solitary BG Left No None Cognitive 10 AZT, 3TC No No
4 Lymphoma 39 sbx Male Solitary BG Right Yes yes Motor 13 Radiation Therapy No Yes
5 PML 32 sbx Male Multiple Frontal Right No None Combined 57 HAART No Yes
6 Toxoplasmosis 24 sbx Male Multiple BG Left Yes Yes Combined 38 HAART,
Antitoxoplasmosis
No No
7 Toxoplasmosis 29 sbx Male Solitary Frontal Right Yes Yes Motor 185 HAART,
Antitoxoplasmosis
No Yes
8 Non Diagnostic × 2
Aspergilosis 3rd
78 sbx Male Multiple Parietal
occipital frontal
Right Yes Yes Motor 50 HAART,
Amphotericin
No No
9 HIV encephalopathy 33 sbx Male Multiple Occipital Right Yes Yes Combined 3 HAART No Yes
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12 Viral infection 37 sbx Male Multiple Frontal Left Yes Yes Combined 36 HAART No No
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15 Viral infection 46 sbx Female Multiple BG Right Yes Yes Combined 33 HAART Bleeding No
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ache, altered mental status, and fever [13].
Diffuse toxoplasmosis encephalitis should be considered
in patients with anti-T gondii immunoglobulin G (IgG)
antibodies and CD4 T-cell counts of <100/μL who present
with unexplained neurologic disease.
Since the introduction of HAART, the incidence of
toxoplasmic encephalitis has remained stable or de-
creased, CNS lymphoma has dramatically declined, PML
has slightly increased, [11] and the incidence of HIV en-
cephalopathy has increased [14]. Although combination
therapies have decreased overall mortality and the preva-
lence of CNS opportunistic infections, these therapies
may be less effective for preventing the direct effects of
HIV-1 on the brain. One of our patients presented with
histologic features of AIDS encephalopathy. The major-
ity of patients in our cohort were men with a median
age of 40, consistent with other studies [15,16]. These
findings are compatible with our data , which is reported
to be increasing in prevalence in the HAART era [17].
Thallium SPECT and PET scanning in the diagnosis of
lymphoma and PCR analysis of the cerebrospinal fluid for
the diagnosis of toxoplasmosis and JC virus have led to a
shift in the use invasive diagnostic techniques (brain bi-
opsy) to noninvasive diagnostic methods [5]. The patient
in our series that was diagnosed with lymphoma had a
solitary enhancing lesion. Although CNS lymphoma gen-
erally tends to enhance, atypical characteristics may be ob-
served on MR images of immunocompromised patients
[18]. Toxoplasma and lymphoma may have similar ap-
pearance on MR imaging. Erdag et al. [18] noted that
lymphoma usually appears as a solitary lesion, unlike
toxoplasmosis, which appears as a multifocal lesion. Only
half of our patients with toxoplasmosis, however, had
multifocal disease, similar to a previous report [15].
The majority of patients in our cohort that were diag-
nosed with PML had nonenhancing lesions, consistent
with previous studies [18,19]. Other studies, however, re-
port enhancement on MR images of PML patients that
may reach 42% [15], and the development of a mass ef-
fect and temporary enhancement on MR images in the
early phase of treatment might represent positive pre-
dictive factors for prolonged survival [19].
A literature review revealed several descriptions of
stereotactic brain biopsy in AIDS patients. The majority
of these were reports on patients treated in the pre-
HAART era [7-9,16,20-26]. In a recent study, Rosenow
et al. [15] divided a large cohort of 246 patients that under-
went brain biopsy into two diagnostic groups, before and
after the HAART era. The authors concluded that the
introduction of HAART led to a steep decrease in the num-
ber of biopsies performed annually. Biopsy led to an object-
ive and definitive diagnosis in 96% of patients (48/50), in
the patients in the HAART era. Definitive diagnoses wereobtained for 91.3% of patients (179/196) in the pre-
HAART era. The overall diagnostic yield of biopsy was
92.3% of the total patient cohort. Rosenow et al. [15] sug-
gested that AIDS patients with intra-cerebral lesions
should undergo toxoplasmosis titers, and those with nega-
tive toxoplasmosis titers should undergo early brain bi-
opsy. In our study, the majority of the patients were
treated in the HAART era, which may correlate with the
relatively small cohort of patients that underwent stereo-
tactic brain biopsy. The diagnostic yield of the biopsy was
high, although lower than previously reported [15].
A total of 19 biopsies were performed in 16 patients;
one procedure was aborted due to bleeding and three bi-
opsies were nondiagnostic (15%). Significantly, two pa-
tients underwent repeated biopsies that were conclusive.
Diagnoses were eventually obtained for 93.7% of patients
(15/16). Based on the biopsy findings, the treatment mo-
dality was modified in 12 patients and led to clinical and
radiologic improvement in 8 patients. Modification of
the treatment following brain biopsy has also been re-
ported [1,8].
Hemorrhagic complications of biopsy are reported
[16,20,23,25]. The incidence of hemorrhage in our small
cohort of patients was higher than that reported in a
non-HIV group of patients treated in our department
[27]. Although the coagulation profile in our patients
was within normal limits, there may have been undetect-
able coagulopathy in this group of patients. Anticoagulo-
pathy regimens have been suggested by others [16] and
pre-biopsy correction of thrombopenia less than
100,000/ml is suggested by Rosenow et al. [15]. A larger
cohort of patients is required to establish more definitive
conclusions.
Conclusion
We present the results from a single institute HAART
era brain biopsy study in a cohort of 16 patients with ac-
tive AIDS-associated lesions. Our objective diagnostic
rates are consistent with those previously reported,
allowing for treatment modification and confirming the
usefulness of biopsy in these patients.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
ZZ and ZRC conducted the study, interpreted the data, and edited the
manuscript. IL and VL were the primary care physicians of the patients,
analyzed and interpreted the data. ZZ, ZRC, MH, and RS performed the
surgical procedures or were part of the decision-making process. DN
reviewed all the pathology and wrote the reports. CH reviewed all the radio-
logical images. JB treated the oncology patient and interpreted the data. CG
reviewed and interpreted the data and edited the manuscript. All authors
read and approved the final manuscript.
Author details
1Department of Neurosurgery, Sheba Medical Center, Ramat Gan, Israel.
2Institute of Pathology, Sheba Medical Center, Ramat Gan, Israel. 3AIDS
Zibly et al. AIDS Research and Therapy 2014, 11:4 Page 5 of 5
http://www.aidsrestherapy.com/content/11/1/4Center, Sheba Medical Center, Ramat Gan, Israel. 4Institute of Radiology,
Sheba Medical Center, Ramat Gan, Israel. 5The Oncology Center, Sheba
Medical Center, Israel, Ramat Gan, Israel. 6Department of Pathology,
Microbiology, and Immunology, University of South Carolina School of
Medicine, Carolina, SC, Columbia. 7National Institute of Neurological
Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Received: 30 March 2013 Accepted: 2 December 2013
Published: 21 January 2014
References
1. Alesch F, Armbruster C, Budka H: Diagnostic value of stereotactic biopsy
of cerebral lesions in patients with AIDS. Acta Neurochir (Wien). 1995,
134(3–4):214–9.
2. Clifford DB: Focal brain lesions in people with HIV. Curr Treat Options
Neurol 1999, 1(2):167–72.
3. Luft BJ, Chua A: Central nervous system toxoplasmosis in HIV
pathogenesis, diagnosis, and therapy. Curr Infect Dis Rep 2000, 2(4):358–62.
4. Narain JP, Raviglione MC, Kochi A: HIV-associated tuberculosis in
developing countries: epidemiology and strategies for prevention.
Tuber Lung Dis 1992, 73(6):311–21. Epub 1992/12/01.
5. Chang L, Miller BL, McBride D, Cornford M, Oropilla G, Buchthal S, et al:
Brain lesions in patients with AIDS: H-1 MR spectroscopy. Radiology 1995,
197(2):525–31.
6. Pomper MG, Constantinides CD, Barker PB, Bizzi A, Dobgan AS, Yokoi F,
et al: Quantitative MR spectroscopic imaging of brain lesions in patients
with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201
SPECT. Acad Radiol 2002, 9(4):398–409.
7. Gervasoni C, Castagna A, Rocca A, Vago L, Cinque P, et al: A comparison
of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS
patients. J Neurol 1997, 244(1):35–9.
8. Viswanathan R, Ironside J, Bell JE, Brettle RP, Whittle IR: Stereotaxic brain
biopsy in AIDS patients: does it contribute to patient management? Br J
Neurosurg 1994, 8(3):307–11.
9. Zimmer C, Marzheuser S, Patt S, Rolfs A, Gottschalk J, Weigel K, et al:
Stereotactic brain biopsy in AIDS. J Neurol 1992, 239(7):394–400.
10. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA,
et al: Declining morbidity and mortality among patients with advanced
human immunodeficiency virus infection. HIV outpatient study
investigators. N Engl J Med 1998, 338(13):853–60.
11. Ammassari A, Cingolani A, Pezzotti P, De Luca DA, Murri R, Giancola ML,
et al: AIDS-related focal brain lesions in the era of highly active
antiretroviral therapy. Neurology 2000, 55(8):1194–200.
12. Vago L, Bonetto S, Nebuloni M, Duca P, Carsana L, Zerbi P, et al:
Pathological findings in the central nervous system of AIDS patients on
assumed antiretroviral therapeutic regimens: retrospective study of 1597
autopsies. Aids 2002, 16(14):1925–8.
13. Renold C, Sugar A, Chave JP, Perrin L, Delavelle J, Pizzolato G, et al:
Toxoplasma encephalitis in patients with the acquired
immunodeficiency syndrome. Med (Baltimore) 1992, 71(4):224–39.
14. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, et al:
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV
encephalopathy in the era of highly active antiretroviral therapy. J Acquir
Immune Defic Syndr 2002, 31(2):171–7.
15. Rosenow JM, Hirschfeld A: Utility of brain biopsy in patients with
acquired immunodeficiency syndrome before and after introduction of
highly active antiretroviral therapy. Neurosurgery 2007, 61(1):130–40.
discussion 40–1.
16. Gildenberg PL, Gathe JC Jr, Kim JH: Stereotactic biopsy of cerebral lesions
in AIDS. Clin Infect Dis 2000, 30(3):491–9.
17. McArthur JC: HIV dementia: an evolving disease. J of neuroimmunol 2004,
157(1–2):3–10. Epub 2004/12/08.
18. Erdag N, Bhorade RM, Alberico RA, Yousuf N, Patel MR: Primary lymphoma
of the central nervous system: typical and atypical CT and MR imaging
appearances. AJR Am J Roentgenol 2001, 176(5):1319–26.
19. Thurnher MM, Post MJ, Rieger A, Kleibl-Popov C, Loewe C, Schindler E:
Initial and follow-up MR imaging findings in AIDS-related progressive
multifocal leukoencephalopathy treated with highly active antiretroviral
therapy. AJNR Am J Neuroradiol 2001, 22(5):977–84.
20. Gildenberg PL, Langford L, Kim JH, Trujillo R: Stereotactic biopsy in
cerebral lesions of AIDS. Acta Neurochir Suppl (Wien) 1993, 58:68–70.21. Levy RM, Breit R, Russell E, Dal Canto MC: MRI-guided stereotaxic brain
biopsy in neurologically symptomatic AIDS patients. J Acquir Immune
Defic Syndr 1991, 4(3):254–60.
22. Levy RM, Russell E, Yungbluth M, Hidvegi DF, Brody BA, Dal Canto MC: The
efficacy of image-guided stereotactic brain biopsy in neurologically
symptomatic acquired immunodeficiency syndrome patients.
Neurosurgery 1992, 30(2):186–9. discussion 9–90.
23. Nielsen CJ, Gjerris F, Pedersen H, Jensen FK, Wagn P: Brain biopsy in
AIDS. Diagnostic value and consequence. Acta Neurochir (Wien) 1994,
127(1–2):99–102.
24. O'Doherty MJ, Lewis P, Nunan TO: Brain biopsy for intracranial mass
lesions in AIDS. Lancet 1993, 341(8839):242–3.
25. Pell MF, Thomas DG, Whittle IR: Stereotactic biopsy of cerebral lesions in
patients with AIDS. Br J Neurosurg 1991, 5(6):585–9.
26. Preuss M, Schumacher HC, Bergs C, Brock M: Brain biopsy for intracranial
mass lesions in AIDS. Lancet 1993, 341(8839):242–3.
27. Grossman R, Sadetzki S, Spiegelmann R, Ram Z: Haemorrhagic
complications and the incidence of asymptomatic bleeding associated
with stereotactic brain biopsies. Acta Neurochir (Wien) 2005, 147(6):627–31.
discussion 31.
doi:10.1186/1742-6405-11-4
Cite this article as: Zibly et al.: Brain biopsy in AIDS patients: diagnostic
yield and treatment applications. AIDS Research and Therapy 2014 11:4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
